高级检索
当前位置: 首页 > 详情页

MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Urology, The First Central Hospital of Baoding, Baoding, Hebei 071000 [2]Department of Urological Surgery,Beijing University People's Hospital, Beijing 100044 [3]Department of Digestive Endoscopy Center,The Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China
出处:
ISSN:

关键词: microRNA-218 cancerous inhibitor of protein phosphatase 2A clear cell renal cell carcinoma tumor suppressor

摘要:
MicroRNAs (miRs) have emerged as critical modulators of tumor initiation and progression in numerous types of human cancer, including clear cell renal cell carcinoma (ccRCC), which is the most common subtype of renal cell carcinoma. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a newly characterized oncoprotein and its overexpression has been reported to promote cellular epithelial-mesenchymal transition and the tumor progression of ccRCC. The present study examined the effects of miR-218 on CIP2A expression in ccRCC cells. The results demonstrated that the expression level of miR-218 was lower in ccRCC tissues compared with that in adjacent non-tumor renal tissues. In addition, it was identified that miR-128 could directly bind to the 3 '-untranslated region of CIP2A. Furthermore, a negative correlation between the expression levels of miR-218 and CIP2A was detected in ccRCC. Additionally, the downregulation of CIP2A or overexpression of miR-218 in ccRCC cells was revealed to inhibit cell proliferation and migration. In summary, these data suggest that miR-218 serves a role in the regulation of CIP2A and elucidate its consequences on tumor progression, tumor cell proliferation and migration. These results indicate that miR-218 may exhibit potential as a molecular target for the treatment of ccRCC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2019]版:
Q3 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Department of Urology, The First Central Hospital of Baoding, Baoding, Hebei 071000 [*1]Department of Urology,The First Central Hospital of Baoding, 320 North Greatwall Street,Lianchi, Baoding, Hebei 071000, P.R. China
通讯作者:
通讯机构: [1]Department of Urology, The First Central Hospital of Baoding, Baoding, Hebei 071000 [*1]Department of Urology,The First Central Hospital of Baoding, 320 North Greatwall Street,Lianchi, Baoding, Hebei 071000, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15101 今日访问量:1 总访问量:961 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号